New Insights and Therapeutic Strategies for HFpEF – A 21st Century Epidemic

Professor John F. O’Sullivan, Cert. Biostat (Harvard), MSc, MD, PhD, FRACP, FAHA, FRCPI

Professor John O’Sullivan is the inaugural Professor of Cardiometabolic Medicine at the University of Sydney and Clinical-Academic Cardiologist in the Department of Cardiology, Royal Prince Alfred Hospital (RPAH). He is Director of the HFpEF ("Stiff Heart Failure") Clinic at RPAH, and Director of the Heart Failure Alliance that incorporates sites across Sydney and Western Sydney Local Health Districts, and also The Alfred Hospital, Melbourne.

John is Lead Principal Investigator on three clinical trials in HFpEF: CardioNAD (ACTRN12622000340730) at RPAH, pEFNAD (ACTRN12622000372785), and pEFEx across the Heart Failure Alliance, which are extensions of his discoveries in the laboratory. He trained at leading institutions in Europe and the USA, including Harvard, Massachusetts General Hospital, and MIT. John is an international expert in heart failure bioenergetics, whose expertise is sought internationally by national grant bodies (e.g. UK, France, Netherlands, Israel, EU, Norway, New Zealand), in addition to medical and cardiac societies. John led the new biomarker theme of the Novel Risk Assessment Expert Subgroup that helped generate the Australian CVD risk Guidelines and Risk Calculator for 12 million Australians over 40. John’s basic science discoveries have been translated to clinical biomarkers, Medicare Item Numbers, new diagnostic assays, and leads a US FDA premarket notification.

In this talk, John will discuss his recent preclinical and clinical work on bioenergetics and meta-inflammatory pathways in Heart Failure with preserved Ejection Fraction (HFpEF).